NCT07479797
Study Evaluating the Efficacy of KITE-753 Versus Axicabtagene Ciloleucel in Participants With Relapsed or Refractory Large B-Cell Lymphoma After First-Line Therapy
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 10 versions: 9 with changes below, 1 re-verified with no change. See every version on ClinicalTrials.gov ↗
- Minor Enrollment closed, study ongoing
- Site details revised at 42 of 42 sites
- Notable Eligibility criteria expanded, about 51 words
- Trial sites expanded: 19 → 42 locations
- Secondary endpoints: details revised at 4 of 11 entries
- Minor Trial sites expanded: 14 → 19 locationsv8
- Minor Trial sites expanded: 10 → 14 locationsv7
- Minor Trial sites expanded: 2 → 10 locationsv6
- Minor Study sites: 1 to 2
- Start date changed from estimate of Aug 2026 to May 22, 2026
- Notable Recruitment opened
- Study sites: 0 to 1
- Notable Eligibility criteria shortened, about 21 wordsv2
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Secondary (11)
Show 6 moreShow less
Arms and interventions
Participants with r/r LBCL will receive the following treatment during the study: * A conditioning chemotherapy regimen of fludarabine and cyclophosphamide. * A single infusion at a target dose of anti-cluster of differentiation 19 (CD19)/CD20 chimeric antigen receptor (CAR) T cells/kg of KITE-753.
Participants with r/r LBCL will receive the following treatment during the study: * A conditioning chemotherapy regimen of fludarabine and cyclophosphamide. * A single infusion at a target dose of anti-CD19/CD20 CAR T cells/kg of axi-cel.
Drugs: KITE-753, Axicabtagene Ciloleucel, Fludarabine, Cyclophosphamide
Sites
42 sites in 9 countries
United States 21, Spain 6, Australia 3, Canada 3, United Kingdom 3, Belgium 2, Japan 2, France 1, Germany 1